Academic Career and Research Areas
Maike Buchner studied Molecular Medicine at the University of Freiburg, completing her Ph.D. in 2010 with 'summa cum laude' under the supervision of Hendik Veelken. Her dissertation focused on "Inhibition of Microenvironmental Pathways: a Novel Therapeutic Approach in Chronic Lymphocytic Leukemia." She then pursued postdoctoral research at the University of California, San Francisco, with Prof. Markus Müschen, focusing on normal B cell development and its progression to Acute Lymphoblastic Leukemia (ALL). Dr. Buchner applies the insights gained from ALL to her current research on Chronic Lymphocytic Leukemia (CLL), also investigating the impact on other immune cells within her research group.
Maike Buchner's research centers on molecular medicine and immunology, aiming to understand the distinct signaling in malignant B cell lymphomas and normal immune cells for therapeutic intervention. Her primary focus is on B cell malignancies, specifically Chronic Lymphocytic Leukemia (CLL) and multiple myeloma (MM). By studying primary patient samples, healthy donors, and preclinical models, she explores the effects of various signaling pathways on disease progression, aiming to identify novel therapeutic interventions. In 2024, Dr. Buchner earned her habilitation at TU Munich, further solidifying her expertise in the field.
Awards
- Max Eder-Stipendium, 2. Förderperiode, Deutsche Krebshilfe (2016)
- Abstract Achievement Award, American Society of Hematology (2015)
- Rückkehrer Stipendium, DAAD (2014)
- Abstract Achievement Award, American Society of Hematology (2013)
- Abstract Achievement Award, American Society of Hematology (2012)
- Promotionspreis, Medizinsche Fakultät Freiburg (2010)
- Promotion ‚summa cum laude’, Fakultät für Biologie / Fakultät für Medizin (2010)
- Promotionsstipendium, Medizinsche Fakultät Freiburg (2006)
Key Publications (all publications)
Ecker, V.*, Stumpf, M.*, Brandmeier, L., Neumayer, T., Ringshausen, I., Pfeuffer, L., Engleitner, T., Ringshausen, I., Nelson, L., Jücker, M., Wanninger, S., Zenz, T., Wendtner, C., Manske, K., Steiger, K., Rad, R., Müschen, M., Ruland, J., Buchner M. (2021) Targeted PI3K/AKT-hyperactivation induces necroptotic cell death in chronic lymphocytic leukemia. Nat Commun. 2021 Jun 10;12(1):3526.
AbstractAlankus, B.*, Ecker, V.*, Vahl, N., Braun, M., Weichert, W., Macher-Göppinger, S., Gehring, T., Neumayer, T., Zenz, T., Buchner, M.#, Ruland, J.# (2021). Pathological RANK signaling in B cells drives autoimmunity and chronic lymphocytic leukemia. J Exp Med. Feb 1;218(2):e20200517.#Co-Senior authors.
AbstractPatzelt, T., Keppler, SJ., Gorka, O., Thöne, S., Wartewig, T., Förster, I., Lang, R., Buchner, M.§, Ruland, J.§ (2018). Foxp1 controls mature B cell survival and the development of follicular and B-1 B cells. Proc Natl Acad Sci U S A. Mar 20;115(12):3120-3125.§Corresponding authors.
AbstractChen Z*, Seyedmehdi S*, Buchner M, Geng H, Lee JW, Klemm L, Titz B, Graeber T, Park E, Tan YX, Satterthwaite A, Paietta E, Hunger SP, Willman CL, Melnick A, Loh M, Jung JU, Coligan JE, Bolland S, Mak T, Limnander A, Jumaa H, Reth M, Weiss A, Lowell CA, Müschen M.: „Signaling thresholds and negative B cell selection in acute lymphoblastic leukemia“ Nature. 2015 May 21;521(7552):357-61.
AbstractEcker, V., Brandmeier, L., Stumpf, M., Giansanti, P., Moreira, A.V., Pfeuffer, L., Fens, M., Lu, J., Kuster, B., Engleitner, T., et al. Buchner, M (2023). Negative feedback regulation of MAPK signaling is an important driver of chronic lymphocytic leukemia progression. Cell Rep 42, 113017.
AbstractIf you wish your profile to be changed or updated please contact TUM Talent Factory.